Production (Stage)
Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.17M | -1.99M | -5.74M | -5.55M | 12.84M |
| Total Depreciation and Amortization | 26.00K | -774.00K | 25.00K | 26.00K | 723.00K |
| Total Amortization of Deferred Charges | 13.00K | 895.00K | 21.00K | 23.00K | 20.00K |
| Total Other Non-Cash Items | 878.00K | 338.00K | 6.25M | 1.33M | 1.60M |
| Change in Net Operating Assets | -4.07M | 52.00K | -2.76M | -4.21M | 23.87M |
| Cash from Operations | -4.32M | -1.47M | -2.21M | -8.39M | 39.05M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -13.00M | -- | -- | -- |
| Issuance of Common Stock | 371.00K | 797.00K | -- | 347.00K | 627.00K |
| Repurchase of Common Stock | -12.00K | -9.00K | -528.00K | -90.00K | -19.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | 0.00 | -1.74M |
| Cash from Financing | 359.00K | -12.21M | -528.00K | 257.00K | -1.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.96M | -13.69M | -2.73M | -8.13M | 37.92M |